Dorsey & Whitney Trust CO LLC Sells 3,888 Shares of Bristol-Myers Squibb (NYSE:BMY)

Dorsey & Whitney Trust CO LLC lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 14.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,576 shares of the biopharmaceutical company’s stock after selling 3,888 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Bristol-Myers Squibb were worth $938,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of BMY. Gryphon Financial Partners LLC raised its holdings in Bristol-Myers Squibb by 23.5% in the 4th quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock worth $280,000 after acquiring an additional 995 shares during the last quarter. Ironwood Investment Counsel LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $253,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Bristol-Myers Squibb by 5.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,067,155 shares of the biopharmaceutical company’s stock valued at $108,112,000 after buying an additional 100,689 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in Bristol-Myers Squibb by 12.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 851,388 shares of the biopharmaceutical company’s stock worth $43,684,000 after buying an additional 96,733 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in Bristol-Myers Squibb by 49.9% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 141,369 shares of the biopharmaceutical company’s stock worth $7,254,000 after buying an additional 47,067 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.6 %

Shares of BMY stock opened at $49.28 on Wednesday. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.42. The company’s fifty day moving average price is $46.27 and its 200-day moving average price is $46.51. The company has a market capitalization of $99.91 billion, a price-to-earnings ratio of -15.90, a PEG ratio of 12.62 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion. During the same period in the previous year, the business earned $1.75 earnings per share. The business’s revenue was up 8.7% on a year-over-year basis. Sell-side analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.87%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BMY shares. Barclays lifted their price target on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a research note on Thursday, August 22nd. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Jefferies Financial Group raised their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research note on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reduced their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $45.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, July 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $54.67.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.